A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test
The study prospectively assesses the change in cancer-specific clinical decisions and outcomes before and after physicians received results from the Pathwork® Tissue of Origin (TOO) Test for patients whose primary site of cancer origin is uncertain.
Neoplasm Metastasis
DEVICE: Pathwork® Tissue of Origin Test
Survival, 2 years
The study prospectively assesses the change in cancer-specific clinical decisions and outcomes before and after physicians received results from the Pathwork® Tissue of Origin (TOO) Test for patients whose primary site of cancer origin is uncertain.